Factors of Influence in 2019, Key Indicators and Opportunity within American Airlines Group, Petroleo Brasileiro S.A.- Petrobras, Gilead Sciences, Baozun, S&P Global, and AVEO Pharmaceuticals — New Research Emphasizes Economic Growth

16-04-2019

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American Airlines Group Inc. (NASDAQ:AAL), Petroleo Brasileiro S.A.- Petrobras (NYSE:PBR), Gilead Sciences, Inc. (NASDAQ:GILD), Baozun Inc. (NASDAQ:BZUN), S&P Global Inc. (NYSE:SPGI), and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AAL DOWNLOAD: https://Capital-Review.com/register/?so=AAL
PBR DOWNLOAD: https://Capital-Review.com/register/?so=PBR
GILD DOWNLOAD: https://Capital-Review.com/register/?so=GILD
BZUN DOWNLOAD: https://Capital-Review.com/register/?so=BZUN
SPGI DOWNLOAD: https://Capital-Review.com/register/?so=SPGI
AVEO DOWNLOAD: https://Capital-Review.com/register/?so=AVEO

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine American Airlines Group Inc. (NASDAQ:AAL), Petroleo Brasileiro S.A.- Petrobras (NYSE:PBR), Gilead Sciences, Inc. (NASDAQ:GILD), Baozun Inc. (NASDAQ:BZUN), S&P Global Inc. (NYSE:SPGI), and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

AMERICAN AIRLINES GROUP INC. (AAL) REPORT OVERVIEW

American Airlines Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, American Airlines Group reported revenue of $10,938.00MM vs $10,610.00MM (up 3.09%) and analysts estimated basic earnings per share $0.69 vs -$1.17. For the twelve months ended December 31st, 2018 vs December 31st, 2017, American Airlines Group reported revenue of $44,541.00MM vs $42,622.00MM (up 4.50%) and analysts estimated basic earnings per share $3.04 vs $2.62 (up 16.03%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.75. The estimated EPS forecast for the next fiscal year is $6.08 and is expected to report on January 23rd, 2020.

To read the full American Airlines Group Inc. (AAL) report, download it here: https://Capital-Review.com/register/?so=AAL

-----------------------------------------

PETROLEO BRASILEIRO S.A.- PETROBRAS (PBR) REPORT OVERVIEW

Petroleo Brasileiro S.A.- Petrobras' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Petroleo Brasileiro S.A.- Petrobras reported revenue of $24,346.00MM vs $23,567.00MM (up 3.31%) and analysts estimated basic earnings per share $0.08 vs -$0.28. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Petroleo Brasileiro S.A.- Petrobras reported revenue of $95,584.00MM vs $88,827.00MM (up 7.61%) and analysts estimated basic earnings per share $1.10 vs -$0.02. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.32. The estimated EPS forecast for the next fiscal year is $1.70 and is expected to report on February 26th, 2020.

To read the full Petroleo Brasileiro S.A.- Petrobras (PBR) report, download it here: https://Capital-Review.com/register/?so=PBR

-----------------------------------------

GILEAD SCIENCES, INC. (GILD) REPORT OVERVIEW

Gilead Sciences' Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Gilead Sciences reported revenue of $22,127.00MM vs $26,107.00MM (down 15.24%) and analysts estimated basic earnings per share $4.20 vs $3.54 (up 18.64%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.37. The estimated EPS forecast for the next fiscal year is $6.28 and is expected to report on February 3rd, 2020.

To read the full Gilead Sciences, Inc. (GILD) report, download it here: https://Capital-Review.com/register/?so=GILD

-----------------------------------------

BAOZUN INC. (BZUN) REPORT OVERVIEW

Baozun's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Baozun reported revenue of $300.62MM vs $255.89MM (up 17.48%) and basic earnings per share $0.47 vs $0.42 (up 11.90%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Baozun reported revenue of $784.38MM vs $637.66MM (up 23.01%) and analysts estimated basic earnings per share $0.69 vs $0.59 (up 16.95%). Analysts expect earnings to be released on May 16th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.04.

To read the full Baozun Inc. (BZUN) report, download it here: https://Capital-Review.com/register/?so=BZUN

-----------------------------------------

S&P GLOBAL INC. (SPGI) REPORT OVERVIEW

S&P Global's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, S&P Global reported revenue of $1,536.00MM vs $1,588.00MM (down 3.27%) and analysts estimated basic earnings per share $2.06 vs $1.05 (up 96.19%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, S&P Global reported revenue of $6,258.00MM vs $6,063.00MM (up 3.22%) and analysts estimated basic earnings per share $7.80 vs $5.84 (up 33.56%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $2.00. The estimated EPS forecast for the next fiscal year is $9.94 and is expected to report on February 6th, 2020.

To read the full S&P Global Inc. (SPGI) report, download it here: https://Capital-Review.com/register/?so=SPGI

-----------------------------------------

AVEO PHARMACEUTICALS, INC. (AVEO) REPORT OVERVIEW

AVEO Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, AVEO Pharmaceuticals reported revenue of $1.48MM vs $0.08MM (up 1,708.54%) and analysts estimated basic earnings per share $0.19 vs $0.03 (up 533.33%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, AVEO Pharmaceuticals reported revenue of $5.41MM vs $7.58MM (down 28.63%) and analysts estimated basic earnings per share -$0.04 vs -$0.61. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is -$0.13 and is expected to report on March 12th, 2020.

To read the full AVEO Pharmaceuticals, Inc. (AVEO) report, download it here: https://Capital-Review.com/register/?so=AVEO

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Latest news
Related news
Related shares
American Airlines Group Inc
VOL 3,509,306
33.26 USD
-0.96 / -2.81 %

Aveo Pharmaceuticals Inc
VOL 2,921,291
0.7614 USD
0.02 / 2.89 %

Petroleo Brasileiro S.A.- Petr
VOL 2,324,101
16.16 USD
-0.03 / -0.19 %

Baozun
VOL 1,310,004
50.00 USD
-3.19 / -6.00 %

Gilead Sciences Inc
VOL 100
66.92 USD
-0.02 / -0.03 %

S&P Global Inc
VOL 195,201
240.42 USD
0.39 / 0.16 %